AbbVie grapples with another setback as 2 PhIII trials for its PARP veliparib flop
Up until now, PARP inhibitors have been blazing a broad, long trail of success in the clinic, with Lynparza, Rubraca and now Zejula hitting a busy and growing market for cancer patients.
But AbbVie $ABBV won’t be joining that crowd anytime soon.
Researchers at the company chose to announce late Wednesday that their PARP, veliparib, failed in two Phase III studies in patients with squamous non-small cell lung cancer (NSCLC) and triple negative breast cancer.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.